Note: Mouseover a species abbreviation on the product page to display the fullname.
How can we help you?
![Blocking/Neutralizing: RelA/NFkB p65 [p Ser276] Inhibitor Peptide Set [NBP2-26505] - Effect of various p65-inhibitor peptides on binding of purified recombinant p65 protein to the DNA in vitro. Recombinant p65 protein (100 ng/sample) was incubated for 30 minutes with 50uM of various peptides in 0.025 ml and then assayed for DNA binding activity by EMSA (Please refer to Takada et al, 2004 for further details).](http://images.novusbio.com/fullsize/RelA-NFkB-p65-[p-Ser276]-Inhibitor-Peptide-Set-Blocking-Neutralizing-NBP2-26505-img0008.jpg "Blocking/Neutralizing: RelA/NFkB p65 [p Ser276] Inhibitor Peptide Set [NBP2-26505] - Effect of various p65-inhibitor peptides on binding of purified recombinant p65 protein to the DNA in vitro. Recombinant p65 protein (100 ng/sample) was incubated for 30 minutes with 50uM of various peptides in 0.025 ml and then assayed for DNA binding activity by EMSA (Please refer to Takada et al, 2004 for further details).")
![Blocking/Neutralizing: RelA/NFkB p65 [p Ser276] Inhibitor Peptide Set [NBP2-26505] - PTD-p65-P1 peptide inhibits TNF-induced NF-kB activation: KBM-5 cells were incubated with various concentrations of peptides for 1 hr and treated with 0.1nM TNF for 30 min. Nuclear extracts were prepared and NF-kB activation was analyzed by EMSA (Please refer to Takada et al, 2004 for further details).](http://images.novusbio.com/fullsize/RelA-NFkB-p65-[p-Ser276]-Inhibitor-Peptide-Set-Blocking-Neutralizing-NBP2-26505-img0009.jpg)
![Functional (Inhibition): RelA/NFkB p65 [p Ser276] Inhibitor Peptide Set [NBP2-26505] - TLR5/NF-kB/SEAPorter HEK 293 (NBP2-26277) cells were plated in 96-well plates at 5 x 10^4 cells/well for 16 h. Cells were preincubated with different concentrations (0, 1, 5, 10, 25 and 50 uM) of Inhibitory Peptide (NBP2-26505) and Control Peptide (NBP2-29334) for 1 h. Cells were then stimulated with 1 ng/ml Flagellin (NBP2-25289) for 24 h. Secreted alkaline phosphatase (SEAP) was analyzed using SEAPorter Assay Kit (NBP2-25285). *p < 0.05 versus control peptide at the corresponding concentrations (Mann-Whitney U test).](http://images.novusbio.com/fullsize/RelA-NFkB-p65-p-Ser276-Inhibitor-Peptide-Set-Functional-Inhibition-NBP2-26505-img0010.jpg)
![Western Blot: RelA/NFkB p65 [p Ser276] Antibody [NB100-82086] - Lane 1: HEK293. Lane 2: Lentivirus mediated NFkB overexpression. We image submitted by a verified customer review.](http://images.novusbio.com/fullsize/RelA-NFkB-p65-[p-Ser276]-Antibody-Western-Blot-NB100-82086-img0015.jpg "Western Blot: RelA/NFkB p65 [p Ser276] Antibody [NB100-82086] - Lane 1: HEK293. Lane 2: Lentivirus mediated NFkB overexpression. We image submitted by a verified customer review.")
![Immunocytochemistry/Immunofluorescence: RelA/NFkB p65 [p Ser276] Antibody [NB100-82086] - Immunofluorescence staining of methanol-fixed MEF cells untreated or treated with TNF using NB100-82086](http://images.novusbio.com/fullsize/RelA-NFkB-p65-[p-Ser276]-Antibody-Immunocytochemistry-Immunofluorescence-NB100-82086-img0011.jpg)
![Immunohistochemistry-Paraffin: RelA/NFkB p65 [p Ser276] Antibody [NB100-82086] - Immunohistochemical analysis of paraffin- embedded human lung carcinoma tissue using NB100-82086](http://images.novusbio.com/fullsize/RelA-NFkB-p65-[p-Ser276]-Antibody-Immunohistochemistry-Paraffin-NB100-82086-img0009.jpg)
![Western Blot: RelA/NFkB p65 [p Ser276] Antibody [NB100-82086] - Analysis of extract from HeLa cells using NF-kB p65 (phospho-Ser276) antibody NB100-82086](http://images.novusbio.com/fullsize/RelA-NFkB-p65-[p-Ser276]-Antibody-Western-Blot-NB100-82086-img0012.jpg)
![Immunocytochemistry/Immunofluorescence: RelA/NFkB p65 [p Ser276] Antibody [NB100-82086] - Staining of methanol-fixed Hela cells.](http://images.novusbio.com/fullsize/RelA-NFkB-p65-[p-Ser276]-Antibody-Immunocytochemistry-Immunofluorescence-NB100-82086-img0014.jpg)
![Immunohistochemistry-Paraffin: RelA/NFkB p65 [p Ser276] Antibody [NB100-82086] - Analysis of paraffin- embedded human breast carcinoma tissue using NB100-82086 (left) or the same antibody preincubated with blocking peptide (right)](http://images.novusbio.com/fullsize/RelA-NFkB-p65-[p-Ser276]-Antibody-Immunohistochemistry-Paraffin-NB100-82086-img0013.jpg)
![Immunohistochemistry-Paraffin: RelA/NFkB p65 [p Ser276] Antibody [NB100-82086] - Human breast carcinoma tissue.](http://images.novusbio.com/fullsize/RelA-NFkB-p65-[p-Ser276]-Antibody-Immunohistochemistry-Paraffin-NB100-82086-img0010.jpg)
![Western Blot: RelA/NFkB p65 [p Ser276] Antibody [NB100-82086] - Western Blot analysis of various cells using NB100-82086 diluted at 1:1000](http://images.novusbio.com/fullsize/nb100-82086_rabbit-polyclonal-rela-nfkb-p65-p-ser276-antibody-23420241545358.jpg)
![Western Blot: RelA/NFkB p65 [p Ser276] Antibody [NBP1-77807] - TNF Induces phosphorylation of p65 in KBM-5 cells. Cytoplasmic and nuclear protein lysates prepared after 0, 5, 10, 15, 30 and 60 minutes of 0.1 nM TNF treatment of KBM-5 cells shows inducible phosphorylation using phospho specific polyclonal anti-human pS276 p65. Pan reactive anti p65 was used a control to show the presence of total p65 in both the cytoplasmic and nuclear extracts. Phosphorylation of p65 occurs after approximately 10 min of TNF exposure. Migration of phosphorylated p65 into the nucleus occurs within a similar time frame. HRP conjugated Gt-anti-Rabbit IgG was used to develop the blot using a chemi -luminescent detection method.](http://images.novusbio.com/fullsize/RelA-NFkB p65 [p Ser276] Antibody-Western Blot-NBP1-77807-img0010.jpg "Western Blot: RelA/NFkB p65 [p Ser276] Antibody [NBP1-77807] - TNF Induces phosphorylation of p65 in KBM-5 cells. Cytoplasmic and nuclear protein lysates prepared after 0, 5, 10, 15, 30 and 60 minutes of 0.1 nM TNF treatment of KBM-5 cells shows inducible phosphorylation using phospho specific polyclonal anti-human pS276 p65. Pan reactive anti p65 was used a control to show the presence of total p65 in both the cytoplasmic and nuclear extracts. Phosphorylation of p65 occurs after approximately 10 min of TNF exposure. Migration of phosphorylated p65 into the nucleus occurs within a similar time frame. HRP conjugated Gt-anti-Rabbit IgG was used to develop the blot using a chemi -luminescent detection method.")
![Immunohistochemistry: RelA/NFkB p65 [p Ser276] Antibody [NBP1-77807] - Diluted to1:500 to detect p65 in human kidney tissue. Tissue was formalin fixed and paraffin embedded. No pre-treatment of sample was required. The image shows the localization of antibody as the precipitated red signal, with a hematoxylin purple nuclear counter stain.](http://images.novusbio.com/fullsize/RelA-NFkB-p65-[p-Ser276]-Antibody-Immunohistochemistry-NBP1-77807-img0007.jpg)
![Western Blot: RelA/NFkB p65 [p Ser276] Antibody [NBP1-77807] - pS529 shows phospho p65 staining in carcinoma cells.](http://images.novusbio.com/fullsize/RelA-NFkB-p65-[p-Ser276]-Antibody-Western-Blot-NBP1-77807-img0005.jpg)
![Western Blot: RelA/NFkB p65 [p Ser276] Antibody [NBP1-77807] - pS276 shows phospho p65 staining in carcinoma cells. Western blot of total protein lysates from various human head and neck tumors shows phospho p65 staining in tumor cell lines using phospho specific polyclonal anti-human pS276 p65. Lanes 1-6 contain protein lysates from human squamal carcinoma cell lines. Lane 7 is a protein lysate from a primary culture of human keratinocytes and does not show significant levels of phosphorylated p65. Lane 8 contains protein lysate from ATCC SCC9 cells (also a head and neck squamal carcinoma). Lane 9 contains lysate from EGF-induced human derived A431 cells. Lane 10 (not shown) contains a molecular weight standard. Concurrent staining with anti-beta microtubulin (not shown) was used to confirm equal protein loading in all lanes. HRP conjugated Gt-anti-Rabbit IgG was used to develop the blot using a chemiluminescent detection method.](http://images.novusbio.com/fullsize/RelA-NFkB-p65-[p-Ser276]-Antibody-Western-Blot-NBP1-77807-img0006.jpg)
![Western Blot: RelA/NFkB p65 [p Ser276] Antibody [NBP1-77807] - TNF Induces phosphorylation of p65 in KBM-5 cells.](http://images.novusbio.com/fullsize/RelA-NFkB-p65-[p-Ser276]-Antibody-Western-Blot-NBP1-77807-img0008.jpg)
![Western Blot: RelA/NFkB p65 [p Ser276] Antibody [NBP1-77827] - Probed against Normal (Lane 1) and TNFalpha (Lane 2) Stimulated HeLa whole cell lysates. A band was observed between 55 and 72 kD corresponding to the expected MW of NFkB p65. The observed higher MW bands have not been characterized.](http://images.novusbio.com/fullsize/RelA-NFkB-p65-[p-Ser276]-Antibody-Western-Blot-NBP1-77827-img0001.jpg "Western Blot: RelA/NFkB p65 [p Ser276] Antibody [NBP1-77827] - Probed against Normal (Lane 1) and TNFalpha (Lane 2) Stimulated HeLa whole cell lysates. A band was observed between 55 and 72 kD corresponding to the expected MW of NFkB p65. The observed higher MW bands have not been characterized.")
![Western Blot: Connexin 35/36 [p Ser 276] Antibody [NBP3-11948] - Western blot of connexin 35/36 fusion proteins showing specific immunolabeling of the ~35 kDa connexin 35/36 phosphorylated at Ser276. The first lane (1) is PKA phosphorylated protein purified from the C-Terminal domain. The second lane (2) shows phosphospecificity indicated by no labeling in protein without PKA stimulation. The third lane (3) is protein purified from the intracellular loop, demonstrating that there is no cross-reactivity with the other major PKA phosphorylation site at Ser110.](http://images.novusbio.com/fullsize/Connexin-35-36-[p-Ser-276]-Antibody-Western-Blot-NBP3-11948-img0001.jpg "Western Blot: Connexin 35/36 [p Ser 276] Antibody [NBP3-11948] - Western blot of connexin 35/36 fusion proteins showing specific immunolabeling of the ~35 kDa connexin 35/36 phosphorylated at Ser276. The first lane (1) is PKA phosphorylated protein purified from the C-Terminal domain. The second lane (2) shows phosphospecificity indicated by no labeling in protein without PKA stimulation. The third lane (3) is protein purified from the intracellular loop, demonstrating that there is no cross-reactivity with the other major PKA phosphorylation site at Ser110.")